Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

AZD-4877

Generic Name: AZD-4877

Drug Type: Small Molecule

Chemical Formula: C_₂₈H_₃₃N_₅O_₂S

CAS Number: 1176760-49-8

Unique Ingredient Identifier: 19ORU63E06

Overview

AZD4877 has been used in trials studying the treatment of NHL, Tumors, Cancer, Lymphoma, and Neoplasms, among others.

Background

AZD4877 has been used in trials studying the treatment of NHL, Tumors, Cancer, Lymphoma, and Neoplasms, among others.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer

Phase 2

Completed

Posted: 2008/04/18

Sponsor:AstraZeneca

ID:NCT00661609

A Phase I, Dose-Escalation Study to Assess the Safety and Drug Levels in Blood of AZD4877 in Japanese Adult Patients

Phase 1

Completed

Posted: 2008/02/13

Sponsor:AstraZeneca

ID:NCT00613652

Phase I/II, Open-label, Multi-center, Two Part Dose-escalation, Safety, Pharmacokinetics (PK) and Efficacy Study of AZD4877 in Patients With Acute Myelogenous Leukemia (AML)

Phase 1

Terminated

Posted: 2007/06/14

Sponsor:AstraZeneca

ID:NCT00486265

Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877

Phase 1

Terminated

Posted: 2007/05/09

Sponsor:AstraZeneca

ID:NCT00471367

Phase I, Open-label, Dose Escalation of AZD4877 in Hematologic Malignancies

Phase 1

Terminated

Posted: 2007/04/16

Sponsor:AstraZeneca

ID:NCT00460460

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy